414 related articles for article (PubMed ID: 18650500)
1. A lesson in moderation: applying pharmacodynamics to clarify the relationship between thiazolidinediones and adverse vascular outcomes in type 2 diabetes.
Lehmann DF; Lohray BB
J Clin Pharmacol; 2008 Aug; 48(8):999-1002. PubMed ID: 18650500
[No Abstract] [Full Text] [Related]
2. [The PPARgamma receptor agonists and prevention of cardio-vascular complications in patients with type 2 diabetes. The results of the PROactive study].
Szymborska-Kajanek A; Strojek K
Kardiol Pol; 2006 Mar; 64(3):322-5; discussion 325-6. PubMed ID: 16583340
[No Abstract] [Full Text] [Related]
3. Peroxisome proliferator-activated receptor gamma agonists: their role as vasoprotective agents in diabetes.
Blaschke F; Caglayan E; Hsueh WA
Endocrinol Metab Clin North Am; 2006 Sep; 35(3):561-74, ix. PubMed ID: 16959586
[TBL] [Abstract][Full Text] [Related]
4. Releasing the pressure.
Davenport RJ
Sci Aging Knowledge Environ; 2005 Jun; 2005(25):nf47. PubMed ID: 15975897
[No Abstract] [Full Text] [Related]
5. Actos and Avandia in type 2 diabetes. Where do they fit?
Clark W
Diabetes Self Manag; 2007; 24(4):8, 11-3. PubMed ID: 17663078
[No Abstract] [Full Text] [Related]
6. Cardiovascular effects of the thiazolidinediones.
Qayyum R; Schulman P
Diabetes Metab Res Rev; 2006; 22(2):88-97. PubMed ID: 16184618
[TBL] [Abstract][Full Text] [Related]
7. [How does the PROactive Study change therapy of diabetes?].
Erdmann E
MMW Fortschr Med; 2005 Oct; 147(41):6. PubMed ID: 16270501
[No Abstract] [Full Text] [Related]
8. [Insulin resistance and atherosclerosis. Controlling diabetes on 2 fronts].
MMW Fortschr Med; 2003 Sep; 145(37):65. PubMed ID: 14584452
[No Abstract] [Full Text] [Related]
9. [Pioglitazone].
Aso Y
Nihon Rinsho; 2012 May; 70 Suppl 3():620-6. PubMed ID: 22768588
[No Abstract] [Full Text] [Related]
10. [New subgroup analysis of the PROactive Study. Risk for recurrent stroke cut in half].
MMW Fortschr Med; 2006 Oct; 148(41):50-1. PubMed ID: 17190265
[No Abstract] [Full Text] [Related]
11. Endothelial dysfunction in patients with type 2 diabetes and the effects of thiazolidinedione antidiabetic agents.
Dandona P; Aljada A
J Diabetes Complications; 2004; 18(2):91-102. PubMed ID: 15120703
[TBL] [Abstract][Full Text] [Related]
12. Thiazolidinediones.
Mascitelli L; Pezzetta F
N Engl J Med; 2005 Jan; 352(2):205-7; author reply 205-7. PubMed ID: 15651125
[No Abstract] [Full Text] [Related]
13. [Timely intervention with insulin sensitizer. Controlling cardiovascular risks].
MMW Fortschr Med; 2003 Jun; 145(23):56-7. PubMed ID: 12854228
[No Abstract] [Full Text] [Related]
14. Thiazolidinediones.
Yki-Järvinen H
N Engl J Med; 2004 Sep; 351(11):1106-18. PubMed ID: 15356308
[No Abstract] [Full Text] [Related]
15. [The benefit of pioglitazone in patients with diabetes mellitus type 2 and cardiovascular complications].
Olsovský J
Vnitr Lek; 2005 Dec; 51(12):1412. PubMed ID: 16430111
[No Abstract] [Full Text] [Related]
16. [Insulin resistance increases risk of infarct. Glitazone now approved also for monotherapy].
MMW Fortschr Med; 2003 Sep; 145(38):61. PubMed ID: 14603688
[No Abstract] [Full Text] [Related]
17. PPAR-gamma: therapeutic target for ischemic stroke.
Culman J; Zhao Y; Gohlke P; Herdegen T
Trends Pharmacol Sci; 2007 May; 28(5):244-9. PubMed ID: 17416424
[TBL] [Abstract][Full Text] [Related]
18. Glitazones in type 2 diabetes: an update.
Drug Ther Bull; 2008 Apr; 46(4):25-9. PubMed ID: 18403615
[TBL] [Abstract][Full Text] [Related]
19. [Glitazones--again].
Halse J
Tidsskr Nor Laegeforen; 2007 Oct; 127(20):2707; author reply 2707. PubMed ID: 17952161
[No Abstract] [Full Text] [Related]
20. [Treatment of patients with type 2 diabetes mellitus with pioglitazone. A survey of a Cochrane review].
Madsbad S
Ugeskr Laeger; 2007 Nov; 169(47):4054-7. PubMed ID: 18078659
[No Abstract] [Full Text] [Related]
[Next] [New Search]
